Citigroup Portfolio holdings
Citigroup Inc., formed in 1998 through the landmark merger of Citicorp and Travelers Group, with roots tracing back to the 1812 founding of City Bank of New York, is a global financial powerhouse headquartered in New York City, managing trillions in assets. Operating in over 160 countries, Citigroup offers a broad spectrum of services, including consumer banking (via Citibank), investment banking, wealth management, and trading, serving millions of retail customers and major corporations, governments, and institutions worldwide. Under CEO Jane Fraser since 2021—the first woman to lead a major U.S. bank—Citigroup has focused on streamlining operations, exiting consumer banking in 13 markets to bolster its institutional and wealth management focus, while navigating post-2008 regulatory scrutiny and fines. Known for its vast global footprint and resilience through crises, Citigroup remains a key player in international finance, blending retail accessibility with high-stakes capital markets expertise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$436M |
| 2 |
United Therapeutics
UTHR
|
+$393M |
| 3 |
Amazon
AMZN
|
+$376M |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$372M |
| 5 |
Visa
V
|
+$364M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI EAFE ETF
EFA
|
+$313M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$272M |
| 3 |
Stellantis
STLA
|
+$222M |
| 4 |
TSMC
TSM
|
+$215M |
| 5 |
Bank of America
BAC
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.76% |
| 2 | Consumer Discretionary | 6.77% |
| 3 | Healthcare | 6.2% |
| 4 | Financials | 5.48% |
| 5 | Communication Services | 4.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4676
Invesco DB Base Metals Fund
DBB
$305M
| $30.2K | ﹤0.01% |
1,500
| – | – |
|
4677
CALL
Valaris Ltd Warrants
VAL.WS
$608M
| $30.2K | ﹤0.01% |
2,303
| – | – |
|
4678
eGain
EGAN
$190M
| $30K | ﹤0.01% |
4,748
+1,310
| +38% | +$8.12K |
|
|
DDL
4679
Dingdong
DDL
$527M
| $29.9K | ﹤0.01% |
15,047
| – | – |
|
4680
ThredUp
TDUP
$760M
| $29.9K | ﹤0.01% |
17,578
+4,040
| +30% | +$7.36K |
|
4681
Peoples Bancorp of North Carolina
PEBK
$231M
| $29.8K | ﹤0.01% |
1,020
-4,911
| -83% | -$144K |
|
4682
Eastern Company
EML
$147M
| $29.7K | ﹤0.01% |
1,168
-4,720
| -80% | -$138K |
|
4683
CPI Card Group
PMTS
$243M
| $29.7K | ﹤0.01% |
1,091
+381
| +54% | +$8.61K |
|
4684
Twin Disc
TWIN
$333M
| $29.5K | ﹤0.01% |
2,506
-23,600
| -90% | -$350K |
|
|
QIPT
4685
DELISTED
Quipt Home Medical
QIPT
| $29.5K | ﹤0.01% |
9,149
+2,273
| +33% | +$8.15K |
|
|
PAMT
4686
PAMT Corp
PAMT
$360M
| $29.5K | ﹤0.01% |
1,697
+209
| +14% | +$3.37K |
|
4687
Acrivon Therapeutics
ACRV
$65.9M
| $29.5K | ﹤0.01% |
5,082
+546
| +12% | +$4.4K |
|
4688
Crawford & Co Class A
CRD.A
$551M
| $29.5K | ﹤0.01% |
3,411
+916
| +37% | +$8.49K |
|
4689
FibroBiologics
FBLG
$3.95M
| $29.5K | ﹤0.01% |
295
-1,226
| -81% | -$234K |
|
4690
Lifecore Biomedical
LFCR
$165M
| $29.5K | ﹤0.01% |
5,743
-122,809
| -96% | -$727K |
|
4691
Schwab Fundamental US Small Company Index ETF
FNDA
$9.24B
| $29.4K | ﹤0.01% |
1,072
-872
| -45% | -$24.1K |
|
4692
Invesco S&P 500 Pure Value ETF
RPV
$1.68B
| $29.3K | ﹤0.01% |
351
| – | – |
|
4693
ProShares UltraShort QQQ
QID
$293M
| $29.1K | ﹤0.01% |
760
-150
| -16% | -$6.63K |
|
|
NAGE
4694
Niagen Bioscience
NAGE
$262M
| $29.1K | ﹤0.01% |
10,652
-52,217
| -83% | -$175K |
|
4695
First National Corp
FXNC
$274M
| $29K | ﹤0.01% |
1,910
-912
| -32% | -$14K |
|
4696
GrowGeneration
GRWG
$88.3M
| $29K | ﹤0.01% |
13,475
+1,168
| +9% | +$2.96K |
|
|
LNAI
4697
Lunai Bioworks
LNAI
$10.2M
| $28.8K | ﹤0.01% |
206
-2,137
| -91% | -$291K |
|
4698
Cadiz
CDZI
$259M
| $28.6K | ﹤0.01% |
9,267
+2,547
| +38% | +$6.92K |
|
4699
Solid Biosciences
SLDB
$785M
| $28.6K | ﹤0.01% |
5,041
-42,671
| -89% | -$382K |
|
4700
Candel Therapeutics
CADL
$709M
| $28.5K | ﹤0.01% |
+4,598
| New | +$34.5K |
|
Similar funds
Citigroup's Q2 2024 Portfolio in Review
As of Q2 2024, Citigroup held 5,888 positions worth $156B, up 2.5% from $152B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Citigroup's Q2 2024 filing shows 274 new, 2,819 increased, 1,798 reduced and 330 closed positions. Its largest new stake was Ferrovial N.V. Ordinary Shares: 8,935,948 shares worth $344M. The largest sale was iShares MSCI EAFE ETF, an estimated $313M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Citigroup's largest Q2 2024 buy was Ferrovial N.V. Ordinary Shares: 8,935,948 shares worth $344M.
- Citigroup added most to Intel in Q2 2024, an estimated $436M increase.
- Citigroup's biggest Q2 2024 reduction was iShares MSCI EAFE ETF, cutting an estimated $313M.
- Citigroup fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $79.7M.
- Citigroup's ten largest holdings make up 22% of its $156B portfolio in Q2 2024.
- Citigroup opened 274 new positions and closed 330 in Q2 2024.
- Citigroup's portfolio value rose 2.5% quarter-over-quarter to $156B.
Based on Citigroup's 13F filing for Q2 2024, filed 12 Aug 2024.